The company is up since yesterday’s close of $18. Shares last traded at $19.10 a tad higher than the 50 day moving average which is $14.97 and marginally over the 200 day moving average of $10.21. The 50 day moving average was up $4.03 or +26.95% and the 200 day average moved up $8.79.
Short traders are feeling a little more bearish on Calithera Biosciences, Inc. recently if you look at the uptick in short interest. The stock realized a rise in short interest of 28.73% as of the latest report on May 31, 2017. Short interest increased 349,332 over that timeframe. With short interest at 1,565,161 and short average daily volume at 915,797, the short-interest ratio is 1.7 and the short interest percentage is 0.04% as of May 31.
Calithera Biosciences, Inc. (NASDAQ:CALA) has been the object of insider selling activity recently. SVP, BUS. & CORP. DEVELOPMENT Curtis Hecht sold 700 shares at an average price of $18.00 on Thu the 6th. Hecht now owns $286,920 of stock per an SEC filing yesterday. Curtis Hecht, SVP, BUS. & CORP. DEVELOPMENT reported the sale of 650 shares. The shares were purchased at an average price of $16.00. Hecht now owns $238,560 of the stock according to the SEC filing.
Calithera Biosciences, Inc., launched on March 9, 2010, is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. The Company is involved in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Business’s lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase..
Here are a few additional firms who have increased or decreased their stake in (CALA). As of quarter end Morgan Stanley had bought a total of 1,438 shares growing its position 36.0%. The value in dollars went from $13,000 to $63,000 a change of $50,000 since the last quarter. As of the end of the quarter Tower Research Capital LLC (trc) had acquired 1,953 shares growing its stake by 114.6%. The value of the total investment in Calithera Biosciences, Inc. increased from $6,000 to $42,000 increasing 600.0% quarter to quarter.
Goldman Sachs Group Inc augmented its investment by buying 117,832 shares an increase of 729.7% as of 03/31/2017. Goldman Sachs Group Inc now holds 133,981 shares valued at $1,547,000. The total value of its holdings increased 2,875.0%. Adage Capital Partners Gp, L.l.c. expanded its ownership by buying 487,804 shares an increase of 13.4%. Adage Capital Partners Gp, L.l.c. claims 4,122,873 shares worth $47,619,000. The value of the position overall is up by 303.1%.
On March 9 JMP Securities left the stock rating at “Market Outperform” but lowered the price target from $20.00 to $12.00. Equity analyst Citigroup added the stock to its research portfolio by announcing an initial rating of “Buy” and a price target of $11.00.
January 28 investment analysts at Citigroup kept the company rating at “Buy” but raised the price expectation to $30.00 from $15.00. On October 27 analysts at Wells Fargo added CALA to its research portfolio setting a rating of “Outperform”.
Citigroup starting coverage on the stock with a rating of “Buy” and setting a price target of $15.00. On October 27, 2014 JMP Securities released its first research report on the stock giving it an initial rating of “Market Outperform” and a price target of $20.00.
As of the last earnings report the EPS was $-1.60 and is expected to be $-0.85 for the current year with 35,294,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.21 with next year’s EPS projected to be $-0.96.